US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 11:00:18 Source:entertainmentViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Warner holds out IPL hot shot Fraser
Next:Australia's deputy prime minister pledges support to Solomon Islands during visit to Honiara
You may also like
- Turkish Airlines resumes flights to Afghanistan nearly 3 years after the Taliban captured Kabul
- At least 37 mothers killed daily in Gaza: medics
- China home to 47 UNESCO Global Geoparks
- Relative of Bianca Censori reveals how she really feels about her marriage to Kanye West
- Fake elector case: Former Arizona GOP chair Kelli Ward and others set to be arraigned
- 86 individuals awarded for helping shield national security
- Xi plants trees in Beijing, urging nationwide afforestation efforts for beautiful China
- Hayao Miyazaki's animated fantasy stays atop Chinese box office
- Protesters against war in Gaza interrupt Blinken repeatedly in the Senate